Dose modification protocol using intravenous busulfan (Busulfex) and cyclophosphamide followed by autologous or allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 9, 2004, Pages 614-623

  Williams, Casey B ^a   Day, Suzanne D ^a   Reed, Michael D ^b   Copelan, Edward A ^c   Bechtel, Thomas ^c   Leather, Helen L ^d   Wingard, John R ^e   Abbott, Brian L ^a   Abhyankar, Sunil ^a   McGuirk, Joseph P ^a  

^a ST LUKE S HOSPITAL   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF FLORIDA   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Bone marrow transplant; Busulfan; Cyclophosphamide; Once daily

Indexed keywords

ANTIEMETIC AGENT; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HLA A ANTIGEN; MESNA; METHOTREXATE; PHENYTOIN;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; AREA UNDER THE CURVE; ARTICLE; ASCITES; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOPSY; BLOOD SAMPLING; BODY WEIGHT DISORDER; CLINICAL ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; EPIDERMOLYSIS; FATIGUE; GASTROINTESTINAL SYMPTOM; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEPATITIS; HERPES SIMPLEX ENCEPHALITIS; HLA MATCHING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; JAUNDICE; LIVER DYSFUNCTION; MUCOSA INFLAMMATION; NAUSEA; PAIN; PARALYTIC ILEUS; PRACTICE GUIDELINE; SEIZURE; STATISTICAL SIGNIFICANCE; VEIN OCCLUSION; VOMITING; WEIGHT GAIN;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; BUSULFAN; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION SCHEDULE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAVENOUS; MIDDLE AGED; PATIENT SELECTION; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 4444242994     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2004.05.010     Document Type: Article

References (41)

1. Andersson B.S. McWilliams K. Tran H. et al. IV busulfan, cyclophosphamide (BuCy) and allogeneic hematopoietic stem cells (BMT) for chronic myeloid leukemia (CML) Blood 92 suppl 1 1998 (abstr. 1168)
2. Kashyap A. Forman S. Cagnoni P. et al. Intravenous busulfan (Busulfex®)/Cytoxan (Cy) preparative regimen for allogeneic (allo) and autologous (auto) hematopoietic stem cell transplantation (BMT) is well tolerated by patients over 50 years of age Blood 92 suppl 1 1998 (abstr. 515)
3. Vaughan W.P. Cagnoni P. Fernandez H. et al. Decreased incidence of and risk factors for hepatic veno-occlusive disease with an IV busulfan (bu) containing preparative regimen for hematopoietic stem cell transplantation (HSCT) Blood 92 suppl 1 1998 (abstr. 2121)
4. Russell J. Tran H. Quinlan D. et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes Biol Blood Marrow Transplant 9 2002 468-476
5. Andersson B. Thall P. Madden T. et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for IV BuCy2 in chronic myelogenous leukemia Biol Blood Marrow Transplant 9 2002 477-485
6. Fernandez H. Tran H. Albrecht F. et al. Evaluation of safety and pharmacokinetics of administering intravenous busulfan in a twice-daily or daily schedule in patients with advanced hematologic malignant disease undergoing stem cell transplantation Biol Blood Marrow Transplant 9 2002 486-492
7. Kashyap A. Wingard J. Cagnoni P. et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic veno-occlusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality Biol Blood Marrow Transplant 9 2002 493-500
8. Andersson B.S. Ashwin K. Gian V. et al. Conditioning therapy with intravenous busulfan and cyclophosphamide (IV BuCy2) for hematological malignancy prior to allogeneic stem cell transplantation: a phase II study Biol Blood Marrow Transplant 8 2002 145-154
9. Santos G.W. Tutschka P.J. Brookmeyer R. et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide N Engl J Med 309 1983 1347-1353
10. Tutschka P.J. Copelan E.A. Klein J.P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide Regimen Blood 70 1987 1382-1388
11. Geller R.B. Saral R. Piantadosi S. et al. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia Blood 73 1989 2209-2218
12. Weaver C.H. Schwartzberg L. Rhinehart S. et al. High-dose chemotherapy with BuCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma Bone Marrow Transplant 21 1998 383-389
13. Ringden O. Labopin M. Tura S. et al. Acute leukemia working party of the European Group for Blood and Marrow Transplantation (EBMT) A comparison of busulfan versus total body irradiation combined with cyclophosphamide as conditioning for autograft or allograft bone marrow transplantation in patients with acute leukemia Br J Haematol 93 1996 637-645
14. Devergie A. Blaise D. Attal M. et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen-a report from the French Society of Bone Marrow Graft (SFGM) Blood 85 1995 2263-2268
15. Blume K.G. Kopecky K.J. Henslee-Downey J.P. et al. A prospective randomized comparison of total body irradiation-etoposide versus busulfan/cyclophosphamide as preparative regimens for bone marrow transplant in patients with leukemia who were not in first remission: a Southwest Oncology Group study Blood 81 1993 2187-2193
16. Andersson BS, Bhagwatar H, Chow D. Parenteral busulfan for treatment of malignant disease. US patents 5,430,057 (1995) and 5,559,148 (1996).
17. Andersson B.S. Madden T. Tran H.T. et al. Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pre-transplantation conditioning therapy: a phase I study Biol Blood Marrow Transplant 6 2000 548-554
18. Miller D.R. Determining Ideal Body Weight and Mass Am J Hosp Pharm 40 1983 1622 [letter]
19. Storb R. Deeg H.J. Whitehead J. et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia N Engl J Med 314 1986 729-735
20. Przepiorka D. Khouri I. Ippoliti C. et al. Tacrolimus and minidose methotrexate for prevention of acute graft-versus-host disease after HLA-mismatched marrow or blood stem cell transplantation Bone Marrow Transplant 24 1999 763-768
21. Gibaldi M. Perrier D. Pharmacokinetics Second Edition 1982 409-417 Marcel Dekker New York
22. Rifai N. Sakanoto M. Lafi M. Guinan E. Measurement of plasma busulfan concentration by high-performance liquid chromatography with ultraviolet detection Ther Drug Monit 19 1997 169-174
23. Jones R.J. Lee K.S. Beschorner W.E. et al. Venoocclusive disease of the liver following bone marrow transplantation Transplantation 44 1987 778-783
24. Bearman S.I. Anderson G.L. Mori M. et al. Venoocclusive disease of the liver: development of a model for predicting fatal outcomes after marrow transplantation J Clin Oncol 9 1993 1729-1736
25. IBMTR Registration Manual. International Bone Marrow Transplant Registry 2001
26. Hassan M. Ehrsson H. Ljungman P. Aspects concerning busulfan pharmacokinetics and bioavailability Leuk Lymphoma 22 1996 395-407
27. Hassan M. Oberg G. Ehrsson H. et al. Pharmacokinetics and metabolic studies of high-dose busulphan in adults Eur J Clin Pharmacol 36 1989 525-530
28. Hassan M. Oberg G. Bekassy A.N. et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology Cancer Chemother Pharmacol 28 1991 130-134
29. Grochow L.B. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens Semin Oncol 20suppl 4 1993 18-25
30. Copelan E.A. Bechtel T.P. Avalos B.R. et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation Bone Marrow Transplant 27 2001 1121-1124
31. Dix S.P. Wingard J.R. Mullins R.E. et al. Association of busulfan area under the curve with veno-occlusive disease following BMT Bone Marrow Transplant 17 1996 225-230
32. Grochow L.B. Jones R.J. Brundett R.B. et al. Pharmacokinetics of high-dose busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation Cancer Chemother Pharmacol 25 1989 55-61
33. Slattery J.T. Sanders J.E. Buckner C.D. et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics Bone Marrow Transplant 16 1995 31-42
34. Ljungman P. Hassan M. Bekassy A.N. et al. High busulfan concentrations are associated with increased transplant-related mortality in allogeneic bone marrow transplant patients Bone Marrow Transplant 20 1997 909-913
35. Slattery J.T. Clift R.A. Buckner C.D. et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation Blood 89 1997 3055-3060
36. Copelan E.A. Penza S.L. Theil K.S. et al. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy Bone Marrow Transplant 26 2000 1037-1043
37. Copelan E.A. Penza S.L. Elder P.J. et al. Analysis of prognostic factors for allogeneic marrow transplantation following busulfan and cyclophosphamide in myelodysplastic syndrome and after leukemic transformation Bone Marrow Transplant 25 2000 1219-1222
38. de Lima M, Couriel D, Thall PF, et al. Once daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood. In press.
39. Hassan M. Ljungman P. Ringden O. et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity Bone Marrow Transplant 25 2000 915-924
40. McDonald G.B. Slattery J.T. Bouvier M.E. et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation Blood 101 2003 2043-2048
41. Wadleigh M. Richardson P.G. Zahreih D. et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation Blood 102 2003 1578-1582